 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 November 1995 | Volume 123 Issue 10 | Pages 747-753
Objective: To evaluate the prevalence of moderate hyperhomocysteinemia and inherited thrombophilia disorders (congenital defects of the natural anticoagulant or fibrinolytic mechanisms) in patients with early-onset venous or arterial thromboembolic disease.
Design: Cross-sectional 2-year evaluation of consecutive unrelated patients with a history of venous or arterial occlusive disease occurring before the age of 45 years or at unusual sites, in the absence of local predisposing factors.
Setting: Thrombosis research unit of a community hospital.
Patients: 107 patients with venous thromboembolism (mean age at event, 32.9 ± 11.9 years) and 50 patients with arterial occlusive disease (mean age at event, 31.1 ± 10 years) who did not have acquired coagulation defects, overt cancer, or acquired conditions affecting methionine metabolism.
Measurements: Total plasma homocysteine (fasting levels), antithrombin III, protein C, protein S, activated protein C resistance, plasminogen, and heparin cofactor II were measured at least 3 months after the event. In 87 patients, total plasma homocysteine levels were also measured 8 hours after an oral methionine load was administered (L-methionine, 0.1 g/kg body weight). Ninety-fifth percentiles of the distribution of these variables were established in 60 apparently healthy persons; sex-specific ranges were used for protein S and total plasma homocysteine. Relatives of patients with laboratory abnormalities were studied to confirm inheritance of the defects.
Results: Moderate hyperhomocysteinemia was detected in 13.1% (95% CI, 7.6% to 21.3%) and in 19.2% (CI, 9.0% to 31.9%) of patients with venous or arterial occlusive disease. The prevalence of hyperhomocysteinemia was almost twice as high when based on homocysteine measurements done after oral methionine load as when based on fasting levels. The remaining defects were detected only in patients with venous occlusive disease (activated protein C resistance in 11.2% of patients, protein S or C deficiency in 6.6%, and plasminogen deficiency in 0.9%), with an overall prevalence of 18.7% (CI, 12.1% to 27.6%). Inheritance of hyperhomocysteinemia and of the other defects was confirmed in 26 of the 30 families studied. Event-free survival analysis showed that the relative risk for occlusive disease in patients with moderate hyperhomocysteinemia and other defects was 1.70 times (CI, 1.19 to 2.42; P < 0.01) greater than in patients without defects. After adjustment for the presence of predisposing factors (for example, use of contraceptive drugs, pregnancy, surgery, prolonged bedrest, smoking, mild hypertension or dyslipidemia) and a family history of thrombosis, the age at first event of patients with moderate hyperhomocysteinemia was similar to that of patients with the other defects (26.4 ± 11.2 years compared with 25.2 ± 10.6 years), and the 43 patients with defects were significantly younger at first event than the 114 patients without defects (25.5 ± 11.1 years compared with 31.0 ± 12.3; P < 0.005). Patients with mild hyperhomocysteinemia had a higher rate of recurrence than those without defects (52% compared with 25%; P = 0.01); among the 56 patients who had their first event more than 1 year before observation, the recurrence rate was higher (80% [CI, 51% to 95%]) in patients with defects than in patients without defects (41% [CI, 26% to 57%] P = 0.01).
Conclusions: Moderate hyperhomocysteinemia may have pathogenic significance in premature venous and arterial occlusive disease and should be included among the (inherited) disorders of venous and arterial thrombophilia.
Author and Article Information
From the Istituto Scientifico IRCCS H. S. Raffaele, Milan, Italy.
ARTICLE
Prevalence of Moderate Hyperhomocysteinemia in Patients with Early-Onset Venous and Arterial Occlusive Disease
Acknowledgments: The authors thank Mrs. Marilena Lomartire and Drs. Omid Safa and Patrizia Della Valle for their invaluable technical assistance.
Grant Support: In part by a grant from the Italian National Research Council (CNR).
Request for Reprints: Isabella Fermo, PhD, Laboratorio Centrale Analisi, Istituto Scientifico H. S. Raffaele, Via Olgettina 60, 20132 Milano, Italy.
Current Author Addresses: Drs. Fermo and Paroni: Laboratorio Analisi, Istituto Scientifico H. S. Raffaele, Via Olgettina 60, 20132 Milano, Italy. Drs. Vigano' D'Angelo, Mazzola, and D'Angelo: Servizio Di Coagulazione, Istituto Scientifico H. S. Raffaele, Via Olgettina 60, 20132 Milano, Italy.
This article has been cited by other articles:
|
|
 |
|
  F. R. Rosendaal Venous Thrombosis: The Role of Genes, Environment, and Behavior Hematology, January 1, 2005; 2005(1): 1 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zijno, C. Andreoli, P. Leopardi, F. Marcon, S. Rossi, S. Caiola, A. Verdina, R. Galati, A. Cafolla, and R. Crebelli Folate status, metabolic genotype, and biomarkers of genotoxicity in healthy subjects Carcinogenesis, June 1, 2003; 24(6): 1097 - 1103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Makin, S.H. Silverman, and G.Y.H. Lip Peripheral vascular disease and Virchow's triad for thrombogenesis QJM, April 1, 2002; 95(4): 199 - 210. [Full Text] [PDF]
|
|
|
|
 |
|
 R. van der Griend, D. H Biesma, and J.-D. Banga Postmethionine-load homocysteine determination for the diagnosis hyperhomocysteinaemia and efficacy of homocysteine lowering treatment regimens Vascular Medicine, February 1, 2002; 7(1): 29 - 33. [Abstract] [PDF]
|
|
|
|
|
|
K. A. Bauer, F. R. Rosendaal, and J. A. Heit Hypercoagulability: Too Many Tests, Too Much Conflicting Data Hematology, January 1, 2002; 2002(1): 353 - 368. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. G. Federman and R. S. Kirsner An Update on Hypercoagulable Disorders Arch Intern Med, April 23, 2001; 161(8): 1051 - 1056. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Guidelines on diagnosis and management of acute pulmonary embolism Eur. Heart J., August 2, 2000; 21(16): 1301 - 1336. [PDF]
|
|
|
|
 |
|
 V. Fonseca, S. C. Guba, and L. M. Fink Hyperhomocysteinemia and the Endocrine System: Implications for Atherosclerosis and Thrombosis Endocr. Rev., October 1, 1999; 20(5): 738 - 759. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. Gemmati, M. Previati, M. L. Serino, S. Moratelli, S. Guerra, S. Capitani, E. Forini, G. Ballerini, and G. L. Scapoli Low Folate Levels and Thermolabile Methylenetetrahydrofolate Reductase as Primary Determinant of Mild Hyperhomocystinemia in Normal and Thromboembolic Subjects Arterioscler. Thromb. Vasc. Biol., July 1, 1999; 19(7): 1761 - 1767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F J Kirkham Stroke in childhood Arch. Dis. Child., July 1, 1999; 81(1): 85 - 89. [Full Text]
|
|
|
|
 |
|
 D. SHEMIN, K. L. LAPANE, L. BAUSSERMAN, E. KANAAN, S. KAHN, L. DWORKIN, and A. G. BOSTOM Plasma Total Homocysteine and Hemodialysis Access Thrombosis: AProspective Study J. Am. Soc. Nephrol., May 1, 1999; 10(5): 1095 - 1099. [Abstract] [Full Text]
|
|
|
|
 |
|
 J.-L. Megnien, J. Gariepy, J.-M. Saudubray, J.-M. Nuoffer, N. Denarie, J. Levenson, and A. Simon Evidence of Carotid Artery Wall Hypertrophy in Homozygous Homocystinuria Circulation, November 24, 1998; 98(21): 2276 - 2281. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Ray Meta-analysis of Hyperhomocysteinemia as a Risk Factor for Venous Thromboembolic Disease Arch Intern Med, October 26, 1998; 158(19): 2101 - 2106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Probst, R. Brandl, M. Blumke, and D. Neumeier Stabilization of Homocysteine Concentration in Whole Blood Clin. Chem., July 1, 1998; 44(7): 1567 - 1569. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Girelli, S. Friso, E. Trabetti, O. Olivieri, C. Russo, R. Pessotto, G. Faccini, P. F. Pignatti, A. Mazzucco, and R. Corrocher Methylenetetrahydrofolate Reductase C677T Mutation, Plasma Homocysteine, and Folate in Subjects From Northern Italy With or Without Angiographically Documented Severe Coronary Atherosclerotic Disease: Evidence for an Important Genetic-Environmental Interaction Blood, June 1, 1998; 91(11): 4158 - 4163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Van Amerongen, F. Mathonnet, C. Boucly, B. Mathieu, I. Vinatier, J.-Y. Peltier, N. Catherine, C. Collet, and P. de Mazancourt An improved method for the detection of the thermolabile variant of methylenetetrahydrofolate reductase Clin. Chem., May 1, 1998; 44(5): 1045 - 1047. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Soriente, A. Coppola, P. Madonna, A. M. Cerbone, G. Di Minno, G. Orefice, A. D'Angelo, and H.S. Markus Homozygous C677T Mutation of the 5,10 Methylenetetrahydrofolate Reductase Gene and Hyperhomocysteinemia in Italian Patients With a History of Early-Onset Ischemic Stroke • Response Stroke, April 1, 1998; 29(4): 869 - 871. [Full Text] [PDF]
|
|
|
|
|
|
M. Cattaneo, M. L. Monzani, I. Martinelli, C. R. Falcon, P. M. Mannucci, and P. M. Ridker Interrelation of Hyperhomocyst(e)inemia, Factor V Leiden, and Risk of Future Venous Thromboembolism • Response Circulation, January 27, 1998; 97(3): 295 - 296. [Full Text]
|
|
|
|
|
|
C. Legnani, G. Palareti, F. Grauso, S. Sassi, G. Grossi, S. Piazzi, F. Bernardi, G. Marchetti, P. Ferraresi, and S. Coccheri Hyperhomocyst(e)inemia and a Common Methylenetetrahydrofolate Reductase Mutation (Ala223Val MTHFR) in Patients With Inherited Thrombophilic Coagulation Defects Arterioscler. Thromb. Vasc. Biol., November 1, 1997; 17(11): 2924 - 2929. [Abstract] [Full Text]
|
|
|
|
|
|
R. W. Evans, B. J. Shaten, J. D. Hempel, J. A. Cutler, and L. H. Kuller Homocyst(e)ine and Risk of Cardiovascular Disease in the Multiple Risk Factor Intervention Trial Arterioscler. Thromb. Vasc. Biol., October 1, 1997; 17(10): 1947 - 1953. [Abstract] [Full Text]
|
|
|
|
|
|
M. Cattaneo, M. Y. Tsai, P. Bucciarelli, E. Taioli, M. L. Zighetti, M. Bignell, and P. M. Mannucci A Common Mutation in the Methylenetetrahydrofolate Reductase Gene (C677T) Increases the Risk for Deep-Vein Thrombosis in Patients With Mutant Factor V (Factor V:Q506) Arterioscler. Thromb. Vasc. Biol., September 1, 1997; 17(9): 1662 - 1666. [Abstract] [Full Text]
|
|
|
|
|
|
A. D'Angelo and J. Selhub Homocysteine and Thrombotic Disease Blood, July 1, 1997; 90(1): 1 - 11. [Full Text] [PDF]
|
|
|
|
 |
|
 A. D'Angelo, I. Fermo, S. V. D'Angelo, I. Quere, H. Lamarti, B. Chadefaux-Vekemans, H. Mandel, B. Brenner, and M. Berant Thrombophilia, Homocystinuria, and Mutation of the Factor V Gene N. Engl. J. Med., July 25, 1996; 335(4): 289 - 290. [Full Text]
|
|
|
|
 |
|
 A. Undas, E. B. Williams, S. Butenas, T. Orfeo, and K. G. Mann Homocysteine Inhibits Inactivation of Factor Va by Activated Protein C J. Biol. Chem., February 2, 2001; 276(6): 4389 - 4397. [Abstract] [Full Text] [PDF]
|
|
Article
